38
Participants
Start Date
February 10, 2018
Primary Completion Date
August 1, 2020
Study Completion Date
November 30, 2020
SHR-1210+GEMOX
28 days as a treatment cycle, SHR-1210 3mg/kg and Gemcitabine 800 mg/m2 will be administered IV Q2W (D1 and D15 of a treatment cycle),and Oxaliplatin 85mg/m2 will be administered IV Q2W (D2 and D16 of a treatment cycle). PD-1 antibody combined chemotherapy used up to 6 cycles.SHR-1210 3mg/kg IV Q2W will be administered beyond chemotherapy until the disease progression or untolerable toxicity.
Jiangsu Province Hospital, Nanjing
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
The First Affiliated Hospital with Nanjing Medical University
OTHER